During the last decade, oral biphosphonates (BP) became the most widely prescribed pharmacologic class for post-menopausal osteoporosis. However, many surveys revealed the important issue of poor persistence with those drugs resulting in a failure of treatment to reduce fracture risk sufficiently. Using a published Markov model, this study analyses the economic impact of non-persistence with biphosphonates in the context of the introduction of generics in France. Link to the article
COTTE, F.E. and PUYOU DE POUVOURVILLE, G. (2011). Cost of Non-Persistence with Oral Biphosphonates in Post-Menopausal Osteoporosis Treatment in France. BMC Health Services Research, 151(11), pp. 1-10.